MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
$19,961K
Free Cash flow
-$32,295K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Sales and maturities of short-te...
Deferred revenue
Stock-based compensation expense
Others
Negative Cash Flow Breakdown
Purchases of short-term investme...
Net loss
Accounts receivable
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2025-09-30
2025-06-30
Net loss
-31,643
-66,761
Stock-based compensation expense
4,308
8,190
Right-of-use asset - operating lease
-292
-568
Amortization (accretion) of premium (discount) on investment securities
764
1,891
Other non-cash items
-77
-88
Accounts receivable
17,243
-
Prepaid expenses and other assets
4,525
8,581
Accounts payable
398
-3,582
Accrued expenses
574
2,480
Operating lease liabilities
-306
-587
Deferred revenue
16,537
-
Net cash used in operating activities
-32,295
-70,076
Purchases of short-term investments
69,747
1,339,835
Sales and maturities of short-term investments
122,000
1,427,000
Purchases of property and equipment
0
590
Net cash provided by (used in) investing activities
52,253
86,575
Proceeds from exercise of stock options and warrants
3
-
Net cash provided by financing activities
3
-
Net increase (decrease) in cash, cash equivalents and restricted cash
19,961
16,499
Cash and cash equivalents at beginning of period
59,820
-
Cash and cash equivalents at end of period
96,280
-
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Sales and maturities
of short-term...
$122,000K
Proceeds from exercise of
stock options and...
$3K
Net cash provided by
(used in) investing...
$52,253K
Net cash provided by
financing activities
$3K
Canceled cashflow
$69,747K
Net increase
(decrease) in cash, cash...
$19,961K
Canceled cashflow
$32,295K
Purchases of short-term
investments
$69,747K
Deferred revenue
$16,537K
Stock-based compensation
expense
$4,308K
Accrued expenses
$574K
Accounts payable
$398K
Right-of-use asset -
operating lease
-$292K
Other non-cash items
-$77K
Net cash used in
operating activities
-$32,295K
Canceled cashflow
$22,186K
Net loss
-$31,643K
Accounts receivable
$17,243K
Prepaid expenses and
other assets
$4,525K
Amortization (accretion) of
premium (discount) on...
$764K
Operating lease
liabilities
-$306K
Buy us a coffee
Astria Therapeutics, Inc. (ATXS)
Astria Therapeutics, Inc. (ATXS)